Exploring Potential Impacts of COVID on Major Depressive Disorder Trial Data
Time: 9:30 am
day: Conference Day One
Details:
- The talk will present the results from CLEO phase 2 trial to assess the safety and efficacy ofbCLE-100 as an adjunctive treatment for Major Depressive Disorder (MDD) with inadequate response to previous antidepressants
- It will explore Potential Impacts of COVID-19 on Major Depressive Disorder Trial Data
- CLE-100 is an oral esketamine tablet formulated with abuse-deterrent technology for daily use at home as an adjunctive treatment for Major Depressive Disorder (MDD) patients with an inadequate response to antidepressants (AD)
